All In Biotech

Drug Trial Radar · NCT07021976

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

228

Actual

Start

Aug 11, 2025

Primary completion

Sep 2026

Study completion Nov 2026

Sponsor

Sponsor type
Industry
First posted
Jun 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.

Conditions

  • Obstructive Hypertrophic Cardiomyopathy

Interventions

  • HRS-1893 TabletsDrug

    HRS-1893 tablets.

  • HRS-1893 Placebo TabletsDrug

    HRS-1893 placebo tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The clinical response rate of treatment with HRS-1893.Time frame: After 24 weeks of HRS-1893 treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.